title: Bronchiectasis in the Last Five Years: New Developments.
abstract: Bronchiectasis, a chronic lung disease characterised by cough and purulent sputum, recurrent infections, and airway damage, is associated with considerable morbidity and mortality. To date, treatment options have been limited to physiotherapy to clear sputum and antibiotics to treat acute infections. Over the last decade, there has been significant progress in understanding the epidemiology, pathophysiology, and microbiology of this disorder. Over the last five years, methods of assessing severity have been developed, the role of macrolide antibiotic therapy in reducing exacerbations cemented, and inhaled antibiotic therapies show promise in the treatment of chronicPseudomonas aeruginosainfection. Novel therapies are currently undergoing Phase 1 and 2 trials. This review aims to address the major developments within the field of bronchiectasis over this time.
authors.affiliation: Department of Respiratory Medicine, Western Health, Melbourne 3011, VIC, Australia. gregkhoo@hotmail.com.
authors.forename: Jun Keng
authors.initials: JK
authors.lastname: Khoo
authors.affiliation: Department of Respiratory Medicine, Prince of Wales, Sydney 2031, NSW, Australia. venningv@gmail.com.
authors.forename: Victoria
authors.initials: V
authors.lastname: Venning
authors.affiliation: Department of Respiratory Medicine, Middlemore Hospital, Auckland 2025, New Zealand. Conroy.Wong@middlemore.co.nz.
authors.forename: Conroy
authors.initials: C
authors.lastname: Wong
authors.affiliation: Department of Respiratory Medicine, Western Health, Melbourne 3011, VIC, Australia. lata.jayaram@unimelb.edu.au.|Melbourne Medical School Western Precinct, The University of Melbourne, Melbourne 3021, VIC, Australia. lata.jayaram@unimelb.edu.au.
authors.forename: Lata
authors.initials: L
authors.lastname: Jayaram
keywords: bronchiectasis; comorbidities; microbiome; severity scores; treatment